We generated eight multiple myeloma cell lines resistant to bortezomib; five acquired
PSMB5 mutations. In 1,500 patients such mutations were rare clinically. To better …

Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …

Introduction: Proteasome inhibition is the backbone of various Multiple Myeloma (MM)
treatment regimens, leading to durable responses and high quality remissions. However …

Multiple myeloma (MM) is a cancer caused by uncontrolled proliferation of antibody-
secreting plasma cells in bone marrow, which represents the second most common …

The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

Variations within proteasome β (PSMB) genes, which encode the β subunits of the 20S
proteasome, may affect proteasome function, assembly, and/or binding of proteasome …

Background Proteasome subunit beta type 1 (PSMB1) rs12717 polymorphism, a single
nucleotide polymorphism with unknown functional effect, was recently reported to influence …

Background Despite encouraging results with the proteasome inhibitor bortezomib in the
treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence …

Background: Various treatment regimen in multiple myeloma (MM) are based on
proteasome inhibition (PI). Although effective at therapy start, most patients relapse and …